Close Menu

NEW YORK (GenomeWeb) – SpeeDx said today that it has entered a test development collaboration with British drugmaker GlaxoSmithKline.

According to Sydney-based SpeeDx, it will provide GSK with a combination of existing and custom-developed molecular diagnostic tests to support its antibiotic clinical trials, as well as its new product development efforts.

Additional terms were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The founder of MeTooSTEM, BethAnn McLaughlin, created a Twitter account purported to be that of an LGBTQ Native American professor at Arizona State University, the New York Times writes.

Novavax reports its candidate SARS-CoV-2 vaccine leads to immune responses, according to the Sydney Morning Herald.

Gene length is associated with lifespan in a comparative genomics study appearing in the Proceedings of the National Academy of Sciences that draws on the whale shark genome.

In Nucleic Acids Research this week: effort to annotate the rat transcriptome, web-based resource to characterize marine microbes, and more.

Aug
18
Sponsored by
Bio-Rad

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Aug
24
Sponsored by
Genecentric

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Aug
25
Sponsored by
Roche

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

Aug
27
Sponsored by
Cellecta

Over 70 percent of breast cancers are estrogen receptor positive and are treated with endocrine therapy.